📊 LNSR Key Takeaways
Is LENSAR, Inc. (LNSR) a Good Investment?
LENSAR is in financial distress with negative stockholders equity (-$26M), indicating the company is technically insolvent on its balance sheet. Despite 13.1% revenue growth, the company burns $14.9M in free cash flow annually against only $13M in cash reserves, creating an unsustainable liquidity crisis. Operating losses of $24.6M and a net margin of -58.7% demonstrate a fundamentally broken business model that lacks a clear path to profitability.
Despite 13% revenue growth, LENSAR remains deeply unprofitable with a -42% operating margin, -59% net margin, and -25.5% FCF margin. Negative stockholders’ equity, weak liquidity (quick 0.62x), and negative interest coverage indicate balance-sheet stress and a likely need for external financing. Until margins and cash burn improve meaningfully, the risk profile outweighs the growth.
Why Buy LENSAR, Inc. Stock? LNSR Key Strengths
- Revenue growth of 13.1% year-over-year shows market demand in surgical instruments sector
- Positive cash balance of $13M provides short-term operational buffer
- Current ratio of 1.15x indicates minimal short-term liquidity obligations coverage
- Double-digit revenue growth (+13.1% YoY)
- Low capital intensity (capex ~$0.08M)
- Current ratio above 1.0x offers limited near-term flexibility
LNSR Stock Risks: LENSAR, Inc. Investment Risks
- Negative stockholders equity of -$26M represents balance sheet insolvency and total shareholder value destruction
- Negative operating cash flow (-$14.8M) and free cash flow (-$14.9M) are unsustainable with only ~1 year of cash runway at current burn rate
- Operating margin of -42.1% and net margin of -58.7% indicate severe operational inefficiency with no clear path to profitability
- Quick ratio of 0.62x signals weak liquidity when excluding inventory, suggesting potential working capital stress
- Liabilities ($83.7M) exceed assets ($71.4M) by $26M, indicating structural insolvency
- Negative equity and weak liquidity suggest going-concern risk
- Persistent losses and negative FCF imply dilution/financing needs
- Negative interest coverage indicates inability to service obligations without improvement
Key Metrics to Watch
- Operating cash flow trajectory toward breakeven
- Cash burn rate and projected runway before potential insolvency event
- Path to positive operating income and evidence of margin expansion
- Revenue per dollar of operating expense (efficiency metric)
- Customer concentration and retention rates in core surgical business
- Operating cash flow and cash runway
- Operating margin trajectory toward break-even
LENSAR, Inc. (LNSR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
LENSAR, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LNSR Profit Margin, ROE & Profitability Analysis
LNSR vs Healthcare Sector: How LENSAR, Inc. Compares
How LENSAR, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LENSAR, Inc. Stock Overvalued? LNSR Valuation Analysis 2026
Based on fundamental analysis, LENSAR, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LENSAR, Inc. Balance Sheet: LNSR Debt, Cash & Liquidity
LNSR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: LENSAR, Inc.'s revenue has grown significantly by 75% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.73 indicates the company is currently unprofitable.
LNSR Revenue Growth, EPS Growth & YoY Performance
LNSR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.8M | -$1.5M | $-0.13 |
| Q2 2025 | $10.7M | -$1.8M | $-0.15 |
| Q1 2025 | $8.6M | -$2.2M | $-0.19 |
| Q3 2024 | $8.3M | -$1.5M | $-0.13 |
| Q2 2024 | $10.3M | -$2.2M | $-0.79 |
| Q1 2024 | $6.6M | -$2.2M | $-0.19 |
| Q3 2023 | $6.3M | $2.6M | $-0.23 |
| Q2 2023 | $6.6M | -$4.3M | $-0.67 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LENSAR, Inc. Dividends, Buybacks & Capital Allocation
LNSR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for LENSAR, Inc. (CIK: 0001320350)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LNSR
What is the AI rating for LNSR?
LENSAR, Inc. (LNSR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LNSR's key strengths?
Claude: Revenue growth of 13.1% year-over-year shows market demand in surgical instruments sector. Positive cash balance of $13M provides short-term operational buffer. ChatGPT: Double-digit revenue growth (+13.1% YoY). Low capital intensity (capex ~$0.08M).
What are the risks of investing in LNSR?
Claude: Negative stockholders equity of -$26M represents balance sheet insolvency and total shareholder value destruction. Negative operating cash flow (-$14.8M) and free cash flow (-$14.9M) are unsustainable with only ~1 year of cash runway at current burn rate. ChatGPT: Negative equity and weak liquidity suggest going-concern risk. Persistent losses and negative FCF imply dilution/financing needs.
What is LNSR's revenue and growth?
LENSAR, Inc. reported revenue of $58.4M.
Does LNSR pay dividends?
LENSAR, Inc. does not currently pay dividends.
Where can I find LNSR SEC filings?
Official SEC filings for LENSAR, Inc. (CIK: 0001320350) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LNSR's EPS?
LENSAR, Inc. has a diluted EPS of $-2.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LNSR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LENSAR, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LNSR stock overvalued or undervalued?
Valuation metrics for LNSR: ROE of N/A (sector avg: 15%), net margin of -58.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LNSR stock in 2026?
Our dual AI analysis gives LENSAR, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LNSR's free cash flow?
LENSAR, Inc.'s operating cash flow is $-14.8M, with capital expenditures of $83.0K. FCF margin is -25.5%.
How does LNSR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -58.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.15 (avg: 2).